SRR8518214
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.430
- MITOTIC_SPINDLE+0.400
- TGF_BETA_SIGNALING+0.370
- INTERFERON_GAMMA_RESPONSE+0.340
- INTERFERON_ALPHA_RESPONSE+0.320
- ANGIOGENESIS+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- INFLAMMATORY_RESPONSE+0.280
- IL6_JAK_STAT3_SIGNALING+0.270
Top 10 suppressed
- ADIPOGENESIS-0.380
- BILE_ACID_METABOLISM-0.320
- CHOLESTEROL_HOMEOSTASIS-0.310
- KRAS_SIGNALING_DN-0.290
- FATTY_ACID_METABOLISM-0.280
- OXIDATIVE_PHOSPHORYLATION-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- XENOBIOTIC_METABOLISM-0.250
- ESTROGEN_RESPONSE_EARLY-0.190
- PEROXISOME-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613802 | — | D | 0.864 |
| 2 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.859 |
| 3 | SRR934821 | — | — | 0.847 |
| 4 | SRR650185 | — | — | 0.847 |
| 5 | SRR650184 | — | — | 0.846 |
| 6 | 198b23eb-5efa-4c7e-84f6-96976474de0b | — | — | 0.846 |
| 7 | C3N-03093 | — | cohortA1 | 0.839 |
| 8 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.836 |
| 9 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.832 |
| 10 | SRR8518233 | — | D | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |